OTCPicks.com

PARADIGM MEDICAL INDUSTRIES (OTCBB: PMED)
"Up 57.14% on Tuesday"

Detailed Quote: http://www.otcpicks.com/quotes/PMED.php

Paradigm Medical Industries, Inc. engages in the design, development, manufacture, and sale of technology surgical and diagnostic eye care products. Its diagnostic products include P55, P2200, and P2500 pachymetric analyzer; P20 and P2000 A-scan biometric ultrasound analyzer; P37, P37-II, and P2700 A/B scan ocular ultrasound diagnostic product; P40 UBM ultrasound biomicroscope; P45 UBM ultrasound biomicroscope; P60 UBM ultrasound biomicroscope; BFA ocular blood flow analyzer and disposables; CT 200 corneal topography system; LD 400 autoperimetry system; and TKS 5000 autoperimetry system. The company's products also comprise Precisionist Thirty Thousand and Photon laser, which have ocular surgery workstation with surgical equipment and disposables. Paradigm's surgical products are systems for use by ophthalmologists to perform surgical treatment procedures to remove cataracts. It markets its products through direct sales representatives, independent sales representatives, and ophthalmic product distributors in the United States, as well as through a network of dealers internationally. The company was founded in 1989 and is based in Salt Lake City, Utah.

PMED News:

March 11 - Paradigm Medical Industries to Introduce Early Glaucoma Detection Device at ASCRS Conference

Paradigm Medical Industries, Inc. (OTCBB: PMED) announced it will introduce the Glaid-PERG electrophysiology instrument for the early detection of glaucoma at the American Society for Cataract Refractive Surgeons (ASCRS) Conference in Chicago, IL, next month.

“All research and studies indicate the Glaid-PERG diagnostic device is the earliest means of detecting cellular losses attributed to glaucoma and other ocular ailments,” said Paradigm Medical’s Chief Executive Officer, Raymond Cannefax. The Company signed an exclusive agreement with LACE Elettronica srl (Rome, Italy) to distribute the Glaid-PERG instrument earlier this year.

After many years of clinical studies at major U.S. and European glaucoma centers, as well as at universities and research centers, the Glaid-PERG has proven to provide high test repeatability and a high level of accuracy. Ongoing research is indicating testing application for ocular ailments other than glaucoma.

“We are excited about the impact the new instrument will have — not only in our industry, but in medical benefits to those who will be diagnosed early as glaucoma suspects,” Mr. Cannefax added. “Early diagnosis will help reduce vision loss and help preserve sight. This is a logical progression in the early detection of glaucoma, the world’s major contributor to vision loss.”

Paradigm Medical will also introduce the prototype version of its redesigned LD400 Autoperimetry system at the ASCRS show. The LD400 is used to measure patient visual fields to determine the severity of glaucoma and to aid in managing the disease.

“The introduction of these two devices is further indication of our Company’s leading technology in eye care,” Mr. Cannefax noted. “It is all part of our ‘Continuous Improvement’ commitment.”

Paradigm Medical Industries, Inc., is a leader in Ultrasound devices, and glaucoma detection and management products.

CHANTICLEER HOLDINGS (OTCBB: CEEH)
"Up 45.45% on Tuesday"

Detailed Quote: http://www.otcpicks.com/quotes/CEEH.php

Chanticleer Holdings, Inc., a business development company, specializes in investing in undervalued small/micro-cap companies. The firm's investment approach is based on the philosophies and strategies of investors, such as Warren Buffett, Benjamin Graham, and Philip Fisher. It aims to manage a low-turnover portfolio of equities while developing a non-operational relationship with those companies and their management. Chanticleer Holdings began operations in June 2005 and is based in Charlotte, North Carolina.

CEEH News:

March 11 - Chanticleer Holdings to Acquire Hooters Inc.

Chanticleer Holdings, Inc. (OTCBB: CEEH) (“Chanticleer”, the “Company”) announced that it has entered into a Stock Purchase Agreement for the purchase of Hooters, Inc., Hooters Management Corporation and their related restaurants (collectively “HI”) from the nine current individual HI shareholders, many of whom will continue to stay involved in the ongoing operation as shareholders of Chanticleer. The transaction is valued at approximately $55.1 million and is anticipated to close on or before July 31, 2008. The final purchase price will be determined after the completion of the 2007 fiscal year audit.

The closing of the transaction is subject to Chanticleer raising the necessary debt and equity financing to complete the acquisition. In addition, Chanticleer will have to convert from its current SEC status as a business development company (“BDC”) to an operating company prior to closing the transaction. Chanticleer has retained an investment banking firm to assist in securing the equity capital necessary to close the proposed transaction.

HI was founded in 1983 and was the creator of the Hooters brand and concept. In 1984, HI licensed Neighborhood Restaurants of America, n/k/a Hooters of America, Inc. (“HOA”), owned by a separate group of shareholders, to be its exclusive licensee in the development and expansion of its restaurant business. In 2001 HI went on to sell the Hooters trademarks and other related proprietary rights to HOA. HI retained and continues to own certain rights including a perpetual irrevocable license agreement with greatly reduced royalties, to operate its restaurants in its retained territories and, most importantly, to acquire franchisees within the Hooters system. These rights will be acquired by Chanticleer as a part of the transaction.

Chanticleer has an existing relationship with HOA through its position as the lead investor in a $5 million, 6% convertible three year promissory note to Robert Brooks, the former Chairman of HOA. This note is secured by and contains conversion options into 2% of Hooters of America outstanding stock. Chanticleer was also granted a right of first refusal and a right to match any equity financing proposed to, or sought by, HOA. Additionally, Chanticleer currently holds an Option Agreement with HOA to open Hooters franchises in the Republic of South Africa which is under active development. The entire Hooters system, consisting of 433 restaurants in 28 countries, is currently celebrating its 25th anniversary with events every 25th of each month and a grand pageant in Miami on July 23, 2008.

Chanticleer CEO, Mike Pruitt, stated, “HI, as the creator of the Hooters brand and concept, owns and operates 22 restaurants, which comprise the highest average unit gross sales within the Hooters system, and includes locations in and around Tampa, Florida, Chicago, Illinois and Manhattan regions, including the original Hooters restaurant located in Clearwater, Florida. We are thrilled to have the opportunity to buy HI and to have the opportunity to work with the strong management team of HI. These assets will substantially increase our investment in the Hooters brand.”

Other affiliated companies of HI, not involved in this transaction, will continue to hold a number of unique and valuable rights, including a license allowing it to sell retail Hooters food products. Other HI affiliates which are not a part of this transaction include the limited liability companies which license, own and operate the world's first Hooters Casino Hotel in Las Vegas, Nevada.

According to Neil Kiefer, CEO of HI, “Mr. Pruitt and his team at Chanticleer have the expertise to structure complex transactions that result in strong financial returns. We believe that this transaction with Chanticleer is in the best interest of the long term future for our Hooters restaurants, its outstanding employees and all stockholders, and will maximize the value of the unique rights of HI and Chanticleer.”

Chanticleer is currently a closed-end investment company that invests in value-based opportunities that are typically either privately held or considered small or micro cap publicly traded companies. Chanticleer has elected to be treated as a business development company (BDC) under the Investment Company Act of 1940 (“1940 Act”) and will continue to operate as a BDC until the closing of this transaction.

Visit www.chanticleerholdings.com for more information about Chanticleer Holdings. Visit www.originalhooters.com or more information about Hooters Inc. Visit www.hooters.com for more information about Hooters of America.

QED CONNECT INCORPORATED (OTC: QEDC)
"Up 37.50% on Tuesday"

Detailed Quote: http://www.otcpicks.com/quotes/QEDC.php

QED Connect, Inc. is an information security Software-as-a-Service (SaaS) provider that gives organizations visibility, management and control of activity on all their computers, laptops and wireless devices. The company's popular SaaS, Omni Manager, is an affordable way to monitor and manage how employees are using company computers and the Internet at any time, from any location in the world. This solves the problems created by today's 'virtual' work environment of branch offices, remote workers and traveling employees. Omni Manager is a web-hosted software application that includes e-mail and Internet filtering and blocking, antivirus, instant messaging management, asset tracking, application usage monitoring and policy management. ROI is delivered by employee productivity gains, cost savings and improved operational efficiencies. For more information, visit www.qedconnect.com.

QEDC News:

February 27 - QED Connect Provides Internet Security and Management Technologies to Spirit Delivery & Distribution

Omni Manager Helps Improve Employee Productivity for Spirit's Call Center Operations

QED Connect, Inc. (OTC: QEDC), an innovative software-as-a-service (SaaS) provider for the information security market, announced that New Jersey-based Spirit Delivery and Distribution Services, Inc., a leading provider of warehousing and delivery services for top U.S. retailers, has chosen its flagship Omni Manager for Internet visibility, management and control. Spirit represents the growing trend of businesses that are choosing hosted technology services over traditional software packages for ease of use, cost savings and reduced administrative responsibilities.

"We had employees challenge using the Internet for non-work related purposes during business hours, and we had no way to control or monitor the web sites being visited," said Jen D'Almeida, Call Center Manager for Spirit Delivery and Distribution Services. "As a call center operation, it's important to get through the highest volume of calls per day as possible. After implementing Omni Manager, we've noticed that our customers are experiencing shorter wait times due to the fact that employees are no longer distracted by the Internet. Using the reporting logs, we can also see what sites they're visiting and attempts to visit blocked sites. One of Omni Manager's biggest benefits is that it's really easy to use and set up. Technology can be complicated, but Omni Manager is very simple and does its job well. It's also a great value for the price."

NEUROGEN CORPORATION (NASD: NRGN)
"Up 21.23% on Tuesday"

Detailed Quote: http://www.otcpicks.com/quotes/NRGN.php

Neurogen Corporation operates as a drug discovery and development company focusing on new small molecule drugs for various disorders, including insomnia, obesity, pain, Parkinson's disease, Restless Legs Syndrome (RLS), and depression/anxiety. Its clinical development programs include NG2-73, which is in phase II clinical trials for the treatment of insomnia; NGD-8243/MK2295, a vanilloid receptor (VR1) antagonist, which is in phase II clinical trials for treating pain; Aplindore, a small molecule partial agonist for the D2 dopamine receptor for the treatment of Parkinson's disease and RLS; and NGD-4715, which is in phase I clinical trial for the treatment of obesity. The company has collaboration agreement with Merck & Co., Inc. to discover and develop drugs targeting VR1 for the treatment of pain. Neurogen was founded in 1987 and is based in Branford, Connecticut.

NRGN News:

March 11 - Neurogen Corporation Announces Webcast of Fiscal 2007 Financial Results on March 17

Neurogen Corporation (NASD: NRGN), a drug discovery and development company, announced that it will release its fiscal 2007 financial results on Monday, March 17, 2008 before the opening of the U.S. financial markets. The Company will host a conference call and live audio webcast that same day at 8:30 a.m. EDT to review the results.

The news release and live webcast may be accessed through the investor relations section of the Company's web site at www.neurogen.com. The webcast will be also be archived in this section, under "Events Calendar and Replays."

CYTOGEN CORPORATION (NASD: CYTO)
"Up 26.09% on Tuesday"

Detailed Quote: http://www.otcpicks.com/quotes/CYTO.php

Cytogen Corporation, a biopharmaceutical company, builds, develops, and commercializes a portfolio of specialty pharmaceutical products for the treatment and care of cancer patients. It markets QUADRAMET (samarium Sm-153 lexidronam injection), PROSTASCINT (capromab pendetide), and SOLTAMOX (tamoxifen citrate) to the United States oncology market. QUADRAMET is approved for the treatment of pain in patients whose cancer has spread to the bone, PROSTASCINT is a prostate-specific membrane antigen (PSMA)-targeting monoclonal antibody-based agent to image the extent and spread of prostate cancer, and SOLTAMOX is the liquid hormonal therapy approved in the U.S. for the treatment of breast cancer in adjuvant and metastatic settings. The company intends to introduce its fourth approved oncology product, CAPHOSOL, an advanced electrolyte solution for the treatment of oral mucositis and dry mouth. CAPHOSOL is approved in the U.S. as a prescription medical device. It is also developing CYT-500, a third-generation radiolabeled antibody to treat prostate cancer. The company was founded in 1980. It was formerly known as Hybridex, Inc. and subsequently changed its name to Cytogen Corporation. Cytogen Corporation is headquartered in Princeton, New Jersey.

CYTO News:

March 11 - Cytogen Announces Definitive Merger Agreement with EUSA PHARMA for $0.62 per Share in Cash

Cytogen Corporation (NASD: CYTO) announced that it has entered into a definitive merger agreement with EUSA Pharma Inc., pursuant to which all outstanding shares of the Company will be converted into $0.62 per share in cash, which represents a premium of approximately 35% over the closing price of $0.46 on March 10, 2008. EUSA Pharma is a transatlantic specialty pharmaceutical company focused on oncology, pain control and critical care.

On November 5, 2007, Cytogen announced it would begin reviewing strategic alternatives to enhance the future growth potential of the Company’s pipeline and maximize shareholder value. In connection with this decision, Cytogen’s Board of Directors formed a special committee of independent directors to consider the Company's options.

Since November 5, 2007, the Special Committee, advised by independent financial and legal advisors, has engaged in a comprehensive and thorough review of strategic alternatives available to Cytogen, which included additional financings, licensing agreements, sale of assets and the sale of the Company. On March 10, 2008, after receiving a fairness opinion, the Board of Directors of Cytogen approved the merger agreement and recommend that Cytogen's stockholders vote in favor of the merger agreement.

Closing of the merger is conditioned on, among other things, the receipt of approval by holders of a majority of the outstanding shares of Cytogen’s common stock, and the parties entrance into a sublicense agreement for the European and Asian rights to the Company’s Caphosol product. It is also subject to certain regulatory review and other customary closing conditions. The transaction is expected to close in the second quarter of 2008. Upon closing of the merger, EUSA Pharma intends to apply to delist all of Cytogen’s issued shares from the NASDAQ Stock Market.

ThinkEquity Partners, LLC acted as financial advisor to Cytogen, Morgan, Lewis & Bockius, LLP acted as legal advisor to Cytogen and Janney Montgomery Scott LLC provided a fairness opinion to the Board of Directors of Cytogen. Ferghana Partners acted as financial advisor to EUSA and McCarter & English, LLP acted as legal advisor to EUSA.

James A. Grigsby, non-Executive Chairman of the Board of Cytogen and member of the Special Committee, said: "We are pleased with the terms of the agreement with EUSA Pharma. This was a thorough process, and we believe this transaction is in the best interests of our stockholders."

ACCESS INTEGR TECHNOLOGIES (NASD: AIXD)
"Up 16.80% on Tuesday"

Detailed Quote: http://www.otcpicks.com/quotes/AIXD.php

Access Integrated Technologies, Inc. (AccessIT) provides integrated solutions for digital cinema in the United States. It offers software and services that enable the motion picture entertainment industry and its constituents to transit from film to digital cinema. The company provides three key integrated solutions: management software and services for distributors and exhibitors; managed electronic delivery of movies and other content using satellite or fiber interchangeably; and vendor agnostic in-theatre application software to serve as the single point of operations and storage for the P.O.S., projection systems, and content in a multiplex. The company's digital cinema networked services along with its Library Management Server and Theatre Command Center enables theatres across the United States to play digital 2-D and 3-D showings of Hollywood features. AccessIT's vendor neutral solutions provide pre-show entertainment, feature movies, and live and pre-recorded alternative content via satellite to expand box office sales. Through its alternative content distribution division, The Bigger Picture, it offers channels of programming, including Kidtoons, Faith Based, Music, High Octane Sports, and Anime. The company was founded in 2000 and is headquartered in Morristown, New Jersey.

AIXD News:

March 11 - Access Integrated Technologies Announces Four Major Studio Agreements Supporting its 'Phase Two' Deployment of up to 10,000 Digital Cinema Projection Systems

Walt Disney Studios, Twentieth Century Fox, Paramount Pictures, and Universal Pictures Agree to Supply Content to Networked Digital Cinema Systems

Access Integrated Technologies (NASD: AIXD) ("AccessIT") announced commitments from four major motion picture studios, including The Walt Disney Studios' Motion Pictures ("WDSMP"), Twentieth Century Fox ("Fox"), Paramount Pictures ("Paramount"), and Universal Pictures ("Universal"), to provide movies to up to 10,000 digital cinema systems in the United States and Canada in conformance with the DCI specifications. These commitments signal the official beginning of AccessIT's "Phase Two" Digital Cinema Program.

AccessIT intends to deploy up to 10,000 systems throughout the U.S. and Canada over the next three years. The studios have agreed to pay virtual print fees, for a limited time only, for movies projected on AccessIT systems, further underscoring their commitment to advance the industry's transition to digital cinema.

"We are thrilled that we have come to an agreement with AccessIT, the global leader in Digital Cinema, to supply content to their 'Phase Two' plan for deployment of networked digital cinema systems," said Chuck Viane, distribution president, WDSMP. "AccessIT's digital cinema rollouts are already allowing consumers to enjoy the highest quality cinema experience available while providing clear benefits to our exhibitors. AccessIT's technologies, management, and financing have aided exhibitors across the U.S. to enter the digital cinema era. We couldn't be more pleased with the top-of- the-line performance of networked digital cinema systems they have deployed which have enabled our movies to be presented in the highest digital viewing quality available."

Bruce Snyder, president of distribution at Twentieth Century Fox, said: "We could not be more pleased. AccessIT's proven ability to bring digital cinema systems to theatres is unmatched in the industry. We believe the efficiency, image quality and, most importantly, the overall movie going experience is greatly enhanced on more than 3,700 of the DCI-conforming digital projection systems already installed by AccessIT throughout the country, and we look forward to supporting our valued partner through this expanded plan by delivering Fox movies to their systems."

Julian Levin, executive vice president Twentieth Century Fox, who spearheaded Fox's participation in the DCI process and who is also the senior Fox architect for this arrangement with AccessIT, added: "The great success the industry is experiencing with the systems already installed by AccessIT makes our continued commitment to the company and to digital cinema a win-win. The benefits resulting from a digital platform include a more efficient and flexible distribution and exhibition infrastructure, as well as digital 3D exhibition capability. We look forward to continuing our relationship with such a great partner."

"AccessIT's proven ability to professionally deploy and manage digital cinema installations helps us provide moviegoers with the most visually enhanced theatre experience possible," said Mark Christiansen, Paramount Pictures' Executive Vice President, Distribution. "This agreement signals yet another important step forward for the future of d-cinema and will also have a major impact on the availability of 3D projection in the U.S. and Canada. We will continue to support the transition to digital cinema by providing our movies, whenever possible, to appropriately equipped theatres."

"This is another major step forward in the transition to Digital Cinema," said Nikki Rocco, Universal's president of distribution. "Universal is pleased to continue working with AccessIT, helping to make digital cinema a reality for more movie-goers across the country. The success of the first AccessIT deployment makes us confident that their next deployment will be equally beneficial for Universal, exhibitors and movie fans."

Chuck Goldwater, president of AccessIT's Media Services Division, added: "AccessIT Digital Cinema's success would not have been possible without the early support of these studios. With their renewed support of this next chapter of our digital cinema program, the industry has a clear signal of the studios' continuing commitment to the digital future and all the benefits of that technology, especially 3D and alternative content. AccessIT is proud to be their trusted partner in making digital cinema happen."

"We appreciate the importance of the signings being announced today as a major step forward for AccessIT and the industry," commented Bud Mayo, chairman and chief executive officer of AccessIT. "This visionary group of major studio partners' endorsement of our Phase Two plan shows the industry that they continue to be extremely forward-thinking in the digital cinema space, and in supporting this venture in particular. We look forward to support from additional studios and exhibitors and to creating more value for the motion picture industry as well as our shareholders."

AccessIT Digital Cinema is the industry-leading deployment program for Digital Cinema that provides the funding, operations and administration for the company's studio-supported Digital Cinema rollout plans. Its Phase Two plan for up to an additional 10,000 screens will provide networked, turnkey, Digital Cinema systems in conformance with DCI specifications, including AccessIT's unique Library Management Server® and Theatre Command Center® software. The system will also include digital projectors and JPEG 2000 media servers from a variety of vendors whose equipment is designed to meet the DCI specifications as well as a demanding set of performance and reliability requirements AccessIT developed through its success with the Phase One plan. To date, AccessIT has contracted for and completed the rollout of more than 3,700 systems in forty-one states with exhibitors, including Atlas Theatres, Allen Theatres, Carmike Cinemas, Celebration! Cinema, Cinema West, Cinetopia, Emagine, Galaxy Cinema, Marquee Cinemas, MJR Theatres, Neighborhood Cinema Group, Rave Motion Picture Theatres, Showplace Cinemas, UltraStar, and AccessIT's own Pavilion Digital Showcase Theatre.